Attention deficit disorder with hyperactivity
Drug research and approvals for attention deficit disorder with hyperactivity: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 163 studies of attention deficit disorder with hyperactivity are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and the EU has 3 authorised medicines for it.
- Recruiting worldwide: 163
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 3
- AI-assisted Home-based Intervention for ADHD ChildrenNCT07922018 · Not applicable · National Taiwan University Hospital · starts Aug 1, 2026
- Micronutrient Supplementation and Chronotherapy in Children With ADHDNCT07922252 · Not applicable · UCSI University · starts Jan 1, 2027
- Multimodal Biomarkers Predicting Medication-Induced Adverse Effects in Children With ADHDNCT07900451 · Not reported · National Taiwan University Hospital · starts Aug 1, 2026
- A Comparison of Group Cognitive Behavioural Therapy (CBT) and Structured Activity Group for Adults With Attention…NCT07834437 · Not applicable · Region Stockholm · starts Sep 1, 2026
- Binaural Beats Stimulation for Adults With Attention-Deficit/Hyperactivity DisorderNCT07793045 · Not applicable · California State University, San Bernardino · starts Mar 3, 2026
- Evaluating the Efficacy of Central Executive Training (CET) For Young Children With ADHDNCT07784348 · Not applicable · Florida State University · starts May 1, 2024
- The Effect of 5-hydroxytryptophan on ADHD Traits and Eye MovementsNCT07777328 · Not applicable · University of Sheffield · starts Nov 25, 2025
- Augmenting Parent Management Training for Child Temper Outbursts Using a Digital ToolNCT07764536 · Not reported · National Institute of Mental Health (NIMH) · starts Nov 25, 2026
- A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional…NCT07759154 · Phase 3 · Otsuka Pharmaceutical Development & Commercialization, Inc. · starts Sep 1, 2026
Approved 23
- MethylphenidateDopamine transporter inhibitor
- AtomoxetineNorepinephrine transporter inhibitor
- LisdexamfetamineDopamine transporter releasing agent
- AmphetamineDopamine transporter releasing agent
- GuanfacineAdrenergic receptor alpha-2 agonist
- ViloxazineNorepinephrine transporter inhibitor
- DextroamphetamineDopamine transporter releasing agent
- ClonidineAdrenergic receptor alpha-2 agonist
- DexmethylphenidateDopamine transporter inhibitor
- ModafinilDopamine transporter inhibitor
- Solriamfetol
- CaffeineAdenosine receptor antagonist
- MethamphetamineMonoamine transporter inhibitor
- Pemoline
- Fipexide
- Pyritinol
- ArmodafinilDopamine transporter inhibitor
- Acetylcarnitine
- IdebenoneAntioxidant and mitochondrial electron carrier
- SerdexmethylphenidateNorepinephrine transporter inhibitor
- Vinpocetine
- Piracetam
- Aceglumate
Phase 3 12
- CentanafadineMonoamine transporter inhibitor
- DasotralineMonoamine transporter inhibitor
- MolindoneDopamine D2 receptor antagonist
- Omega-3-ACID ethyl esters
- MelatoninMelatonin receptor agonist
- BupropionDopamine transporter inhibitor
- ZolpidemGABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator
- CyclophosphamideDNA inhibitor
- Doconexent
- Maritime pine
- Omega-3 fatty acids
- Citicoline
Phase 2 12 of 50
- PozaniclineNicotinic acetylcholine receptor alpha4/beta2/alpha5 partial agonist
- BavisantHistamine H3 receptor antagonist
- PyridoxineSupplement
- BradaniclineNeuronal acetylcholine receptor protein alpha-7 subunit agonist
- EdivoxetineNorepinephrine transporter inhibitor
- Theanine
- Fasoracetam
- Phosphatidyl serine
- AripiprazoleDopamine D2 receptor partial agonist
- DuloxetineSerotonin transporter inhibitor
- QuetiapineSerotonin 2a (5-HT2a) receptor antagonist
- VortioxetineSerotonin 1a (5-HT1a) receptor agonist
Phase 1 or earlier 10
- CalcitriolVitamin D receptor agonist
- NicotineNeuronal acetylcholine receptor; alpha4/beta2 agonist
- CiforadenantAdenosine A2a receptor antagonist
- ND0801Neuronal acetylcholine receptor protein alpha-7 subunit agonist
- BetahistineHistamine H3 receptor antagonist
- Potassium gluconate
- TAK-137
- LidocaineSodium channel alpha subunit blocker
- OxytocinOxytocin receptor agonist
- AmilorideAmiloride-sensitive sodium channel, ENaC blocker
How its trials ended
1,272 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 304 whose ending is known, 65% met their primary endpoint, 9% missed it and 26% stopped early.
- Completed, result not reported62449%
- Met its primary endpoint19916%
- Status unknown17614%
- Ongoing16813%
- Stopped: other or unclear484%
- Missed its primary endpoint262%
- Stopped: enrollment or feasibility161%
- Stopped: lack of efficacy6<1%
- Stopped: sponsor or business decision6<1%
- Stopped: funding3<1%
| Feb 28, 2025 | TuzulbyMethylphenidate hydrochloride | Neuraxpharm Pharmaceuticals S.L. | EMA ↗ |
| Feb 26, 2025 | PaxneuryGuanfacine · generic | Neuraxpharm Pharmaceuticals S.L. | EMA ↗ |
| Sep 17, 2015 | IntunivGuanfacine | Takeda Pharmaceuticals International AG Ireland | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA